NCT03382977 2025-03-11
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
VBI Vaccines Inc.
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT00669669 2022-05-18
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT00984438 2019-11-25
Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
University of Cincinnati
Phase 1/2 Withdrawn
NCT00027612 2016-12-07
Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00003417 2015-11-17
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00009854 2013-11-06
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00005855 2013-06-21
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed